Cargando…
Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442637/ https://www.ncbi.nlm.nih.gov/pubmed/34524645 http://dx.doi.org/10.1007/s13577-021-00616-x |
| _version_ | 1783753043116818432 |
|---|---|
| author | Panda, Aditya K. Padhi, Sunali Pati, Abhijit Nayak, Tapan Kumar Singh |
| author_facet | Panda, Aditya K. Padhi, Sunali Pati, Abhijit Nayak, Tapan Kumar Singh |
| author_sort | Panda, Aditya K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8442637 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84426372021-09-15 Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted Panda, Aditya K. Padhi, Sunali Pati, Abhijit Nayak, Tapan Kumar Singh Hum Cell Letter to the Editor Springer Singapore 2021-09-15 2021 /pmc/articles/PMC8442637/ /pubmed/34524645 http://dx.doi.org/10.1007/s13577-021-00616-x Text en © Japan Human Cell Society 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Panda, Aditya K. Padhi, Sunali Pati, Abhijit Nayak, Tapan Kumar Singh Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted |
| title | Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted |
| title_full | Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted |
| title_fullStr | Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted |
| title_full_unstemmed | Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted |
| title_short | Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted |
| title_sort | efficacy of il-6 antagonists in the treatment of covid-19 patients: further randomized controlled trials are warranted |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442637/ https://www.ncbi.nlm.nih.gov/pubmed/34524645 http://dx.doi.org/10.1007/s13577-021-00616-x |
| work_keys_str_mv | AT pandaadityak efficacyofil6antagonistsinthetreatmentofcovid19patientsfurtherrandomizedcontrolledtrialsarewarranted AT padhisunali efficacyofil6antagonistsinthetreatmentofcovid19patientsfurtherrandomizedcontrolledtrialsarewarranted AT patiabhijit efficacyofil6antagonistsinthetreatmentofcovid19patientsfurtherrandomizedcontrolledtrialsarewarranted AT nayaktapankumarsingh efficacyofil6antagonistsinthetreatmentofcovid19patientsfurtherrandomizedcontrolledtrialsarewarranted |